Contineum Therapeutics (CTNM) risk factors, FY2025 10-K

Risks Related to Development, Clinical Testing, and Regulatory Approval

1. 01comparable regulatory authorities for this indication. Furthermore, as more competing drug candidates within a class of drugs proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or changeNew
2. 02materially harmed. Further, under the terms of our License Agreement with J&J, J&J has sole discretion to determine whether to pursue further development of PIPE-307 for RRMS, MDD or any other indicationNew
3. 03We have and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities or ethics committees may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business and financial condition
4. 04The timely completion of clinical trials in accordance with their protocols depends, among other things, on the ability to enroll a sufficient number of patients who remain in the trial until its conclusion54% rewritten
5. 05Interim and preliminary “top-line” data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data
6. 06The administration of PIPE-791 and/or PIPE-307 may cause serious adverse events or undesirable side effects, which may halt their clinical development, delay or prevent marketing approval, or, if approved, require them to be taken off the market, include safety warnings, or otherwise limit their sales
7. 07Any of these events could prevent us or J&J, as applicable, from achieving or maintaining market acceptance of PIPE-791 or PIPE-307, if approved, and could significantly harm our business, financial condition, results of operations and prospects67% rewritten
8. 08The market opportunities for the drug candidates we develop, if approved, may be smaller than we anticipate and, as a result, our commercial opportunities may be limited
9. 09We have never obtained marketing approval for any drug candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any drug candidate
10. 10Even if we obtain FDA approval for a drug candidate in the United States, we may never obtain approval for the drug candidate in any other jurisdiction or commercialize the drug candidate in the United States or in any other jurisdiction, which would limit our ability to realize its full market potential
11. 11Even if we obtain regulatory approval for any drug candidate, we will still face extensive and ongoing regulatory requirements and obligations, which may result in significant additional expense, and any drug candidates, if approved, may face future development and regulatory difficulties80% rewritten
12. 12Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any products that we may develop
13. 13The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges

Risks Related to our Financial Position and Need for Additional Capital

1. 14We have a limited operating history and the drug candidates we have developed are in the early stages of clinical development, which may make it difficult to evaluate the prospects for our future viability
2. 15We will require significant additional capital to complete the development and commercialization of PIPE-791 and the other drug candidates we select for development47% rewritten

Risks Related to our Existing Collaboration Agreement and any Collaboration Agreements we may enter into in the Future

1. 16If the J&J License Agreement does not result in the successful development of PIPE-307, our business, financial condition and results of operations will be harmed25% rewritten
2. 17We may not recognize the financial and other benefits of any additional collaborations or strategic alliances that we may enter into in the future for the development and commercialization of our drug candidates67% rewritten

Risks Related to our Intellectual Property

1. 18regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidatesNew
2. 19Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time
3. 20If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any drug candidates we may develop, our business may be materially harmed28% rewritten
4. 21Hatch-Waxman Act. Thus, if one of our licensed patents is eligible for patent term extension under the Hatch-Waxman Act, we may not be able to control whether a petition to obtain a patent term extension is filed, or obtained, from the USPTONew
5. 22Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 23If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed
7. 24Although we are not currently involved in any litigation, we may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful
8. 25Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
9. 26Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities
10. 27Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
11. 28We may not be able to protect our intellectual property and proprietary rights throughout the world
12. 29We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
13. 30If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
14. 31If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
15. 32Intellectual property rights do not necessarily address all potential threats

Risks Related to our Dependence on Third Parties

1. 33We intend to rely on CROs, and other third parties to conduct our preclinical studies. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business
2. 34Our third-party manufacturers may be unable to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity, which could delay or prevent us from developing our drug candidates and commercializing approved products, if any
3. 35Manufacturing of the API for PIPE-791 takes place in China, through a sole third-party manufacturer. A significant disruption in the operation of this manufacturer could materially adversely affect our business, financial condition and results of operations

Risks Related to Healthcare Laws and Other Legal Compliance Matters

1. 36Recent and future changes in healthcare legislation and regulations may increase the difficulty and cost to obtain marketing approval for a drug candidate, increase the costs to commercialize an approved product, and adversely affect the price set for such product
2. 37The ACA and its implementation continue to evolve as a result of legislative, administrative, and judicial developments. Further changes remain possible, which may potentially negatively affect pricing, coverage, or reimbursement for PIPE-791 and/or PIPE-307
3. 38Our business operations and current and future relationships with contractors, investigators, healthcare professionals, consultants, third-party payors, patient organizations, customers, and others will be subject to applicable healthcare regulatory laws, which could expose us to penalties
4. 39Any clinical trial programs, marketing, or research collaborations in the European Economic Area will subject us to the GDPR
5. 40We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities

Risks Related to our Employees, Managing our Growth and our Operations

1. 41Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel
2. 42We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
3. 43Our business and operations could be materially and adversely affected in the event of system failures29% rewritten
4. 44Our proprietary or confidential information may be lost, or we may suffer security breaches

Risks Related to Commercialization

1. 45We face significant competition from biotechnology, pharmaceutical, and medical device companies, and our operating results will suffer if we fail to compete effectively and in a timely manner
2. 46PIPE-791 for Chronic Pain87% rewritten
3. 47There are numerous approved therapies for depression, including antidepressant drugs such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, antipsychotics and mood stabilizers. A number of these approved therapies are offered as genericsNew
4. 48Even if PIPE-791 or PIPE-307 receives marketing approval in an indication, it may fail to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community necessary for commercial success
5. 49We have no sales, marketing or distribution capabilities or experience. If we are unable to establish sales and marketing capabilities either on our own or in collaboration with third parties, we may not be successful in commercializing PIPE-791, even if approved
6. 50The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for an approved products could limit the ability to market the product and decrease the revenues we ultimately receive62% rewritten
7. 51requirements, penalties, or other sanctions, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospectsNew
8. 52A variety of risks associated with operating internationally could materially adversely affect our business32% rewritten

Risks Related to Ownership and our Common Stock

1. 53The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders
2. 54We have a limited trading history and there is no assurance that a robust market in our common stock will develop or be sustained
3. 55Sales of a substantial number of shares of our common stock in the public market could cause the price of our common stock to fall27% rewritten
4. 56Our directors, executive officers and holders of greater than 5% of our common stock own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant influence over matters subject to stockholder approval
5. 57The dual series structure of our Class A and Class B common stock may limit your ability to influence corporate matters and may limit your visibility with respect to certain transactions62% rewritten
6. 58transactions in our Class B common stock pursuant to Section 16(a) of the Exchange Act of 1934, as amended (the “Exchange Act”), and may not be subject to the short-swing profit provisions of Section 16(b) of the Exchange ActNew
7. 59We are an “emerging growth company,” and a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies or smaller reporting companies will make our common stock less attractive to investors74% rewritten
8. 60We do not intend to pay cash dividends for the foreseeable future. Consequently, you must rely on sales of our common stock after price appreciation, which may never occur, as the only way to realize any future gains on your investment
9. 61Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock
10. 62If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
11. 63We could be subject to securities class action litigation
12. 64Requirements associated with being a public company have and will continue to increase our costs significantly, as well as divert significant company resources and management attention
13. 65Unstable or unfavorable global economic conditions and an uncertain geopolitical environment could have an adverse effect on our business, financial condition, results of operations and prospectsNew
14. 66Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited
15. 67Changes in tax laws and the implementation of tax laws could adversely affect us37% rewritten